Exelixis, Inc. (EXEL)
56.89
+2.25
(+4.12%)
USD |
NASDAQ |
Sep 01, 16:00
56.72
-0.17
(-0.30%)
After-Hours: 20:00
Exelixis Cash from Investing (Quarterly) : 91.43M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 91.43M |
| March 31, 2026 | -51.07M |
| December 31, 2025 | 27.24M |
| September 30, 2025 | 25.40M |
| June 30, 2025 | 248.03M |
| March 31, 2025 | 49.76M |
| December 31, 2024 | -93.20M |
| September 30, 2024 | -217.15M |
| June 30, 2024 | 81.77M |
| March 31, 2024 | 111.79M |
| December 31, 2023 | 61.74M |
| September 30, 2023 | 34.68M |
| June 30, 2023 | -73.78M |
| March 31, 2023 | -49.59M |
| December 31, 2022 | -245.78M |
| September 30, 2022 | -68.95M |
| June 30, 2022 | -135.14M |
| March 31, 2022 | -74.54M |
| December 31, 2021 | -13.06M |
| September 30, 2021 | -21.24M |
| June 30, 2021 | -70.84M |
| March 31, 2021 | 62.26M |
| December 31, 2020 | -29.51M |
| September 30, 2020 | -207.60M |
| June 30, 2020 | 73.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 32.62M |
| December 31, 2019 | -130.20M |
| September 30, 2019 | -206.46M |
| June 30, 2019 | -142.93M |
| March 31, 2019 | -107.66M |
| December 31, 2018 | -142.80M |
| September 30, 2018 | -63.25M |
| June 30, 2018 | -66.27M |
| March 31, 2018 | -25.53M |
| December 31, 2017 | -18.83M |
| September 30, 2017 | -26.59M |
| June 30, 2017 | 46.72M |
| March 31, 2017 | 34.50M |
| December 31, 2016 | -60.41M |
| September 30, 2016 | -12.13M |
| June 30, 2016 | -123.82M |
| March 31, 2016 | -19.68M |
| December 31, 2015 | 24.01M |
| September 30, 2015 | -31.51M |
| June 30, 2015 | 7.685M |
| March 31, 2015 | 49.90M |
| December 31, 2014 | 30.18M |
| September 30, 2014 | 11.10M |
| June 30, 2014 | 44.69M |
| March 31, 2014 | 60.36M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| BioMarin Pharmaceutical, Inc. | -5.102B |
| Cytokinetics, Inc. | -507.00M |
| Emergent BioSolutions, Inc. | -52.30M |
| Gilead Sciences, Inc. | -10.35B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 307.74M |
| Cash from Financing (Quarterly) | -343.88M |
| Free Cash Flow | 1.172B |
| Free Cash Flow Per Share (Quarterly) | 1.159 |
| Free Cash Flow to Equity (Quarterly) | 304.54M |
| Free Cash Flow to Firm (Quarterly) | 300.92M |
| Free Cash Flow Yield | 7.62% |